Patients would pay no more than $25 for certain name-brand medications to treat chronic illnesses, and face no costs for ...

India to continue to allow the sale of Ranitidine, a drug under scrutiny for potential cancer risks due to NDMA impurities.

Sergel is heading towards generating Tk 1,000 crore in annual sales as over Tk 900 crore worth of the gastrological medicine ...